CA1235659A - Composes pharmaceutiques et methode de preparation de composes de phosphatidylserine utiles pour le traitement des troubles du snc sans effet sur la coagulation du sang - Google Patents

Composes pharmaceutiques et methode de preparation de composes de phosphatidylserine utiles pour le traitement des troubles du snc sans effet sur la coagulation du sang

Info

Publication number: CA1235659A
Authority: CA; Canada
Prior art keywords: phosphatidylserine; phosphatidylethanolamine; weight percent; extract; solution
Prior art date: 1984-11-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000467847A

Other languages

English (en)

Inventor

Francesco Della Valle

Aurelio Romeo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fidia SpA

Original Assignee

Fidia SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-11-14

Filing date

1984-11-14

Publication date

1988-04-26

1984-11-14 Application filed by Fidia SpA filed Critical Fidia SpA

1984-11-14 Priority to CA000467847A priority Critical patent/CA1235659A/fr

1988-04-26 Application granted granted Critical

1988-04-26 Publication of CA1235659A publication Critical patent/CA1235659A/fr

Status Expired legal-status Critical Current

Links

TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title claims abstract description 158
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title claims abstract description 158
239000000203 mixture Substances 0.000 title claims abstract description 113
230000000694 effects Effects 0.000 title claims abstract description 54
238000000034 method Methods 0.000 title claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 title claims description 15
230000023555 blood coagulation Effects 0.000 title description 6
208000015114 central nervous system disease Diseases 0.000 title description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 claims abstract description 80
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 79
150000003904 phospholipids Chemical class 0.000 claims abstract description 64
230000015271 coagulation Effects 0.000 claims abstract description 22
238000005345 coagulation Methods 0.000 claims abstract description 22
230000008569 process Effects 0.000 claims abstract description 16
230000002195 synergetic effect Effects 0.000 claims abstract description 8
229940067631 phospholipid Drugs 0.000 claims description 68
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 22
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 21
241001465754 Metazoa Species 0.000 claims description 19
210000005013 brain tissue Anatomy 0.000 claims description 17
229960001701 chloroform Drugs 0.000 claims description 11
238000001914 filtration Methods 0.000 claims description 10
230000001376 precipitating effect Effects 0.000 claims description 7
230000003291 dopaminomimetic effect Effects 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
238000001556 precipitation Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims 4
210000003169 central nervous system Anatomy 0.000 abstract description 11
238000002360 preparation method Methods 0.000 abstract description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
239000000243 solution Substances 0.000 description 26
230000002490 cerebral effect Effects 0.000 description 21
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 11
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
108010094028 Prothrombin Proteins 0.000 description 10
102100027378 Prothrombin Human genes 0.000 description 10
239000008103 glucose Substances 0.000 description 10
229940039716 prothrombin Drugs 0.000 description 10
241000700159 Rattus Species 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 7
210000004556 brain Anatomy 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
150000002500 ions Chemical class 0.000 description 5
230000007170 pathology Effects 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
230000032683 aging Effects 0.000 description 4
238000013019 agitation Methods 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
239000002502 liposome Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
229960002646 scopolamine Drugs 0.000 description 4
230000002792 vascular Effects 0.000 description 4
208000024827 Alzheimer disease Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
102000003946 Prolactin Human genes 0.000 description 3
108010057464 Prolactin Proteins 0.000 description 3
108010000499 Thromboplastin Proteins 0.000 description 3
102000002262 Thromboplastin Human genes 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000701 coagulant Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229940045641 monobasic sodium phosphate Drugs 0.000 description 3
229910000403 monosodium phosphate Inorganic materials 0.000 description 3
235000019799 monosodium phosphate Nutrition 0.000 description 3
230000014508 negative regulation of coagulation Effects 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
229940097325 prolactin Drugs 0.000 description 3
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
208000027776 Extrapyramidal disease Diseases 0.000 description 2
208000026680 Metabolic Brain disease Diseases 0.000 description 2
206010062190 Metabolic encephalopathy Diseases 0.000 description 2
206010029216 Nervousness Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
206010039966 Senile dementia Diseases 0.000 description 2
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
235000013871 bee wax Nutrition 0.000 description 2
239000012166 beeswax Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000003710 cerebral cortex Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
229940061607 dibasic sodium phosphate Drugs 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000000955 neuroendocrine Effects 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
DJMUYABFXCIYSC-UHFFFAOYSA-N 1H-phosphole Chemical compound C=1C=CPC=1 DJMUYABFXCIYSC-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101000648554 Mus musculus Sushi domain-containing protein 6 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000440 effect on coagulation Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000021824 exploration behavior Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940041476 lactose 100 mg Drugs 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000005065 mining Methods 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
230000001379 nervous effect Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
125000001095 phosphatidyl group Chemical group 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008307 presynaptic mechanism Effects 0.000 description 1
230000026234 pro-estrus Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000003236 psychic effect Effects 0.000 description 1
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000002739 subcortical effect Effects 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000001026 thromboplastic effect Effects 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000007306 turnover Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA000467847A 1984-11-14 1984-11-14 Composes pharmaceutiques et methode de preparation de composes de phosphatidylserine utiles pour le traitement des troubles du snc sans effet sur la coagulation du sang Expired CA1235659A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000467847A CA1235659A (fr)	1984-11-14	1984-11-14	Composes pharmaceutiques et methode de preparation de composes de phosphatidylserine utiles pour le traitement des troubles du snc sans effet sur la coagulation du sang

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000467847A CA1235659A (fr)	1984-11-14	1984-11-14	Composes pharmaceutiques et methode de preparation de composes de phosphatidylserine utiles pour le traitement des troubles du snc sans effet sur la coagulation du sang

Publications (1)

Publication Number	Publication Date
CA1235659A true CA1235659A (fr)	1988-04-26

Family

ID=4129152

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000467847A Expired CA1235659A (fr)	1984-11-14	1984-11-14	Composes pharmaceutiques et methode de preparation de composes de phosphatidylserine utiles pour le traitement des troubles du snc sans effet sur la coagulation du sang

Country Status (1)

Country	Link
CA (1)	CA1235659A (fr)

1984
- 1984-11-14 CA CA000467847A patent/CA1235659A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2005-04-26	MKEX	Expiry

Publication	Publication Date	Title
EP0148045B1 (fr)	1988-06-29	Compositions pharmaceutiques et procédé de préparation de compositions contenant de la phosphatidylsérine pour le traitement des troubles du système nerveux central sans effets sur la coagulation du sang
JPS6241688B2 (fr)	1987-09-04
US5474991A (en)	1995-12-12	Lipid metabolism improving medicinal composition
US20170027966A1 (en)	2017-02-02	Tumor eradication by inositol-tripyrophosphate
EP0201623B1 (fr)	1990-02-07	Compositions pharmaceutiques pour le traitement des syndromes involutifs du cerveau et du déclin mental
EP0026223A1 (fr)	1981-04-08	Procede et composition pour le traitement des troubles par administration de lecithine
CZ355897A3 (cs)	1998-02-18	Způsob léčení mánie a bipolárních poruch
Busey et al.	2023	Analogs of FTY720 inhibit TRPM7 but not S1PRs and exert multimodal anti-inflammatory effects
US20060241086A1 (en)	2006-10-26	Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin
Drenckhahn et al.	1979	Experimental myopathy induced by amphiphilic cationic compounds including several psychotropic drugs
Piredda et al.	1986	Effects of antiepileptic drugs on pentylenetetrazole‐induced epileptiform activity in the in vitro hippocampus
GB2045612A (en)	1980-11-05	Pharmaceutical compositions containing phosphatidic acids for the treatment of disorders of consciousness perception and movement
KR950005914B1 (ko)	1995-06-07	Nmda-차단 제약조성물
BE881238A (nl)	1980-07-18	Farmaceutisch preparaat en werkwijze ter bereiding daarvan
Epstein	1960	Synthetic antimalarial drug therapy in lupus erythematosus and polymorphous light eruptions
Busey et al.	2023	Novel TRPM7 inhibitors with potent anti-inflammatory effects in vivo
KR100259175B1 (ko)	2000-06-15	엘-무스콘의 의약용도
JP2820698B2 (ja)	1998-11-05	脳機能改善剤
IT202100032252A1 (it)	2023-06-22	Processo di estrazione e purificazione industriale di fosfolipidi
EP0260606A2 (fr)	1988-03-23	Médicament contenant du sialocylglycérolipide pour guérir des troubles ou des maladies neurotiques
Shinitzky	1986	The lipid regimen
EA051183B1 (ru)	2025-10-13	Промышленный способ извлечения и очистки фосфолипидов
WO2017044002A1 (fr)	2017-03-16	Principe actif d'un médicament, médicament, composition pharmaceutique et méthode de traitement de maladies à démyélinisation affectant un organisme vivant, y compris prévention de maladies
JPH0717507B2 (ja)	1995-03-01	抗血栓剤
JPH0212932B2 (fr)	1990-03-30